CareDx, IncCDNANASDAQ
Loading

Latest News

Bamco Inc. NY Has $45.88 Million Stake in CareDx, Inc. $CDNA
defenseworld.net

Bamco Inc. NY Has $45.88 Million Stake in CareDx, Inc. $CDNA

Bamco Inc. NY grew its stake in shares of CareDx, Inc. (NASDAQ: CDNA) by 29.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,155,180 shares of the company's stock after buying an additional 719,523 shares during the period. Bamco

CareDx Details Transplant+ Roadmap, AlloHeme Timeline, and 2026 Outlook at Raymond James Conference
defenseworld.net

CareDx Details Transplant+ Roadmap, AlloHeme Timeline, and 2026 Outlook at Raymond James Conference

CareDx (NASDAQ: CDNA) executives outlined the company's transplant-focused strategy, recent financial performance, and 2026 priorities during remarks at the Raymond James Institutional Investor Conference. Chief Operating Officer and recently appointed Chief Financial Officer Keith Kennedy and Chief Commercial Officer Jessica Meng described CareDx's position in solid organ transplant diagnostics and services, and provided additional detail around

CareDx Announces VANTx™, an AI‑Powered Clinical Data & Analytics Platform Built on CareDx's Proprietary, Large-Scale, Longitudinal Solid Organ Transplant Datasets
businesswire.com

CareDx Announces VANTx™, an AI‑Powered Clinical Data & Analytics Platform Built on CareDx's Proprietary, Large-Scale, Longitudinal Solid Organ Transplant Datasets

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the launch of VANTx™, an AI‑powered, cloud‑native clinical data and analytics platform designed to transform complex transplant data into insights that support clinical research and real‑world.

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the award of inducement grants. On February 24, 2026, as an inducement material to acceptance of employment with CareDx, 35 new employees were awarded restricted stock units (RSUs) for an agg.

CareDx Announces Appointment of Keith Kennedy as Chief Operating Officer and Chief Financial Officer
businesswire.com

CareDx Announces Appointment of Keith Kennedy as Chief Operating Officer and Chief Financial Officer

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced that Keith Kennedy, the Company's Chief Operating Officer (COO), will also assume the responsibilities of Chief Financial Officer (CFO) and oversee the Company's finance organization effective.

CareDx Announces Fourth Quarter and Full Year 2025 Financial Results
businesswire.com

CareDx Announces Fourth Quarter and Full Year 2025 Financial Results

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Highlights Revenue of $108 million, an increase of 25% year-over-year Testing servic.

Comparing CareDx (NASDAQ:CDNA) and Elevance Health (NYSE:ELV)
defenseworld.net

Comparing CareDx (NASDAQ:CDNA) and Elevance Health (NYSE:ELV)

CareDx (NASDAQ: CDNA - Get Free Report) and Elevance Health (NYSE: ELV - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, earnings and profitability. Volatility and Risk CareDx has a beta of 2.51,

Thrivent Financial for Lutherans Cuts Holdings in CareDx, Inc. $CDNA
defenseworld.net

Thrivent Financial for Lutherans Cuts Holdings in CareDx, Inc. $CDNA

Thrivent Financial for Lutherans cut its holdings in CareDx, Inc. (NASDAQ: CDNA) by 75.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,452 shares of the company's stock after selling 38,218 shares during the quarter.

CareDx to Participate in the Raymond James 47th Annual Institutional Investors Conference
businesswire.com

CareDx to Participate in the Raymond James 47th Annual Institutional Investors Conference

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the company will participate in the Raymond James 47th Annual Institutional Investors Conference in Orlando, FL on Tuesday, March 3, 2026. About CareDx CareDx is a precision medicine company de.

Baron Discovery Fund Q4 2025: Winners, Laggards, Buys & Sells
seekingalpha.com

Baron Discovery Fund Q4 2025: Winners, Laggards, Buys & Sells

In the fourth quarter of 2025, the Baron Discovery Fund returned 0.19% (Institutional Shares), trailing the Russell 2000 Growth Index by 1.03%. In these periods, low quality (high debt and poor profitability) and short-term price momentum-oriented stocks outperformed. Exact Sciences Corporation received a buyout offer in the fourth quarter by Abbott Laboratories (ABT) for a price of $105 in cash.

CareDx Announces Clinical Validation Results for AlloHeme™, the First AI‑Powered NGS Surveillance Solution for AML and MDS Post‑Cell Therapy
businesswire.com

CareDx Announces Clinical Validation Results for AlloHeme™, the First AI‑Powered NGS Surveillance Solution for AML and MDS Post‑Cell Therapy

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced pivotal clinical validation results of AlloHeme™, a non-invasive, next‑generation sequencing (NGS)–based, and artificial intelligence (AI)-powered monitoring test designed to predict relapse in.

CareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
businesswire.com

CareDx to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced it will report financial results for the fourth quarter and full year 2025 after market close on Tuesday, February 24, 2026. The Company will host a webcast and conference call that day at 1:30.

CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings
businesswire.com

CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced that pivotal clinical validation data from the ACROBAT study (NCT04635384) will be presented at the 2026 Tandem Meetings, Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®,.